DGAP-News: Heidelberg Pharma AG
/ Key word(s): Conference
31.03.2021 / 08:09
The issuer is solely responsible for the content of this announcement.
Heidelberg Pharma to Present New Data on its Proprietary ATAC Technology Platform at the AACR Annual Meeting 2021
Ladenburg, Germany, 31 March 2021 – Heidelberg Pharma AG (FSE: HPHA) announced today that it will present preclinical data on its novel ATAC candidates HDP-102 and HDP-103 as well as data on synergistic effects of ATACs with checkpoint inhibitors at the American Association for Cancer Research (AACR) 2021 Annual Meeting. The meeting will be held in a virtual format from April 10 – 15, 2021.
Details of the poster presentation – PSMA ATACs:
The poster presentation will cover preclinical data on ATACs targeting PSMA (prostate-specific membrane antigen). This surface protein is overexpressed on prostate tumor cells and can therefore also be used as a biomarker. We show that ATACs targeting PSMA possess high antitumor activity and inhibit tumor growth in animal models even at low concentrations. The favorable safety profile due to the good tolerability of these ATACs confirms that they may represent a promising new therapeutic option against prostate cancer.
Details of the poster presentation – CD37 ATACs:
The poster shows preclinical data on CD37 ATACs. CD37 is a protein that is overexpressed on B-cell lymphoma cells. The data presented show that CD37-ATACs have high antitumor activity and inhibit the growth of hematologic tumors even at low concentrations. The good tolerability of the different ATACs is a further confirmation that CD37 ATACs may represent a promising therapeutic option against certain B-cell lymphomas.
Details of the poster presentation – immuno-oncology:
The poster shows preclinical data on the use of ATACs together with immune checkpoint inhibitors. Treatment of cancer cells with ATACs triggers their immunogenic cell death, leading to activation of the immune system. Combining this immunostimulatory property of ATACs with immune checkpoint inhibitors may represent a promising approach for further oncological therapies.
Online poster presentations will be available on the AACR website (https://www.aacr.org/meeting/aacr-annual-meeting-2021/) beginning Saturday, 10 April 2021, 2:30 PM CEST (8:30 AM US EDT).
On the company website, the posters will be available under “Press & Investors > Calendar and Presentations > Scientific Posters” from 16 April 2021.
About Heidelberg Pharma’s proprietary ATAC technology
About Heidelberg Pharma
Heidelberg Pharma AG is listed on the Frankfurt Stock Exchange: ISIN DE000A11QVV0/ WKN A11QVV / Symbol HPHA. The More information is available at www.heidelberg-pharma.com.
This communication contains certain forward-looking statements relating to the Company’s business, which can be identified by the use of forward-looking terminology such as “estimates”, “believes”, “expects”, “may”, “will” “should” “future”, “potential” or similar expressions or by a general discussion of the Company’s strategy, plans or intentions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results of operations, financial condition, performance, or achievements, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Given these uncertainties, prospective investors and partners are cautioned not to place undue reliance on such forward-looking statements. We disclaim any obligation to update any such forward-looking statements to reflect future events or developments.
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
|Company:||Heidelberg Pharma AG|
|Phone:||+49 (0)89 41 31 38 – 0|
|Fax:||+49 (0)89 41 31 38 – 99|
|Listed:||Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Munich, Stuttgart, Tradegate Exchange|
|EQS News ID:||1179970|
|End of News||DGAP News Service|